重要的生物标志物可以预测和估计不同类型淋巴瘤对化疗的反应。经典霍奇金淋巴瘤（cHL）和外周T细胞淋巴瘤（PTCL）属于不同类型的淋巴瘤，它们的预后差异很大，程序性细胞死亡受体1（PD-1）及其配体（PD-L1）已被研究这2种疾病。然而，很少有研究涉及 cHL 和 PTCL 之间 PD-1/PD-L1 水平的差异。为了找出差异及相关临床应用价值，我们采集了29例初诊cHL患者和11例初诊PTCL患者的血液样本。同时收集13例cHL患者初诊时的肿瘤组织石蜡切片。采用流式细胞术、酶联免疫吸附法、免疫组化染色检测患者外周血T细胞、血浆、肿瘤组织中PD-1/PD-L1的水平，以及上述结果与患者临床资料的关系与 cHL 进行了研究。 cHL、PTCL患者外周血CD4+T细胞上PD-1、CD4+T细胞上PD-L1、CD8+T细胞上PD-1水平高于健康对照者,CD4+T细胞上PD-1水平III-IV期cHL患者外周血T细胞较高（P = .0178），B症状（P = .0398），乳酸脱氢酶较高（P = .0056），国际预后指数评分较高（P = .0398）。 0349），后期复发（P = .0306）。 cHL（P < .001）和PTCL（P < .0001）患者可溶性PD-L1（sPD-L1）表达水平高于健康对照组，且患者中sPD-L1水平较高具有较高的国际预后指数评分（P = .0016）。动态检测sPD-L1显示，化疗2个疗程后，完全缓解cHL患者sPD-L1水平下降，但不完全缓解患者sPD-L1水平无明显变化（P > .05） 。 cHL患者肿瘤组织中，PD-1( )为77%，PD-L1( )为69%，PD-1和PD-L1表达水平较高。我们的研究结果提示，外周血CD4 T细胞中PD-1水平有助于cHL患者的疾病分期，动态检测sPD-L1水平有助于cHL患者的判断。Copyright © 2023 作者（s）。由 Wolters Kluwer Health, Inc. 出版

Significant biomarkers can predict and estimate the response to chemotherapy for different types of lymphoma. Classical Hodgkin's lymphoma (cHL) and peripheral T-cell lymphoma (PTCL) belong to different types of lymphoma, their prognosis is very different, programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) have been studied in these 2 types of diseases. However, few studies have involved the difference in PD-1/PD-L1 levels between cHL and PTCL. To find out the difference and relevant clinical application value, we collected blood samples of 29 newly diagnosed cHL patients and 11 newly diagnosed PTCL ones. At the same time, tumor tissue paraffin sections of 13 patients with cHL were collected at the initial diagnosis. Flow cytometry, enzyme-linked immunosorbent assay, and immunohistochemical staining were used to detect PD-1/PD-L1 levels in peripheral blood T cells, plasma, and tumor tissues, and the relationship between the above results and clinical data of patients in patients with cHL were investigated. The levels of PD-1 on CD4+ T cells, PD-L1 on CD4+ T cells and PD-1 on CD8+ T cells in peripheral blood of cHL and PTCL patients were higher than those of healthy controls, the level of PD-1 in CD4+ T cells from peripheral blood was higher from cHL patients with stage III-IV (P = .0178), B symptoms (P = .0398), higher lactate dehydrogenase (P = .0056), higher international prognostic index score (P = .0349), and relapsed in later stages (P = .0306). The expression level of soluble PD-L1 (sPD-L1) from cHL (P < .001) and PTCL (P < .0001) patients was higher than that of the healthy control group, and there was higher sPD-L1 level in patients with higher international prognostic index scores (P = .0016). The dynamic detection of sPD-L1 showed that after 2 courses of chemotherapy, the sPD-L1 level in cHL patients with complete remission declined, but the level of sPD-L1 from patients with incomplete remission was not significantly changed (P > .05). In tumor tissues of cHL patients, PD-1(+) was 77%, PD-L1(+) was 69%, PD-1 and PD-L1 expression levels were high. Our results suggest that PD-1 levels in peripheral blood CD4+ T cells are helpful for the stage of disease in patients with cHL, and the dynamic detection of sPD-L1 level is helpful for the judgment of patients with cHL.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.